nodes	percent_of_prediction	percent_of_DWPC	metapath
Icatibant—BDKRB2—myometrium—ovarian cancer	0.0499	0.0855	CbGeAlD
Icatibant—BDKRB2—uterine cervix—ovarian cancer	0.0388	0.0665	CbGeAlD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—RRAS2—ovarian cancer	0.0379	0.113	CbGpPWpGaD
Icatibant—BDKRB2—decidua—ovarian cancer	0.037	0.0634	CbGeAlD
Icatibant—BDKRB2—endometrium—ovarian cancer	0.0351	0.0602	CbGeAlD
Icatibant—BDKRB2—uterus—ovarian cancer	0.0324	0.0554	CbGeAlD
Icatibant—ANPEP—myometrium—ovarian cancer	0.0311	0.0533	CbGeAlD
Icatibant—ANPEP—embryo—ovarian cancer	0.0299	0.0513	CbGeAlD
Icatibant—BDKRB2—female reproductive system—ovarian cancer	0.0291	0.0498	CbGeAlD
Icatibant—BDKRB2—female gonad—ovarian cancer	0.0265	0.0453	CbGeAlD
Icatibant—BDKRB2—vagina—ovarian cancer	0.0263	0.0451	CbGeAlD
Icatibant—ANPEP—epithelium—ovarian cancer	0.0244	0.0418	CbGeAlD
Icatibant—ANPEP—uterine cervix—ovarian cancer	0.0242	0.0415	CbGeAlD
Icatibant—BDKRB2—testis—ovarian cancer	0.0235	0.0402	CbGeAlD
Icatibant—ANPEP—decidua—ovarian cancer	0.0231	0.0395	CbGeAlD
Icatibant—BDKRB2—Validated transcriptional targets of deltaNp63 isoforms—TP63—ovarian cancer	0.023	0.0686	CbGpPWpGaD
Icatibant—ANPEP—Peptide hormone metabolism—INHA—ovarian cancer	0.022	0.0655	CbGpPWpGaD
Icatibant—ANPEP—endometrium—ovarian cancer	0.0219	0.0375	CbGeAlD
Icatibant—ANPEP—uterus—ovarian cancer	0.0202	0.0346	CbGeAlD
Icatibant—BDKRB2—Validated transcriptional targets of deltaNp63 isoforms—YAP1—ovarian cancer	0.0189	0.0564	CbGpPWpGaD
Icatibant—ANPEP—female reproductive system—ovarian cancer	0.0181	0.0311	CbGeAlD
Icatibant—ANPEP—bone marrow—ovarian cancer	0.0171	0.0293	CbGeAlD
Icatibant—BDKRB2—lymph node—ovarian cancer	0.017	0.0292	CbGeAlD
Icatibant—BDKRB2—Direct p53 effectors—CD82—ovarian cancer	0.0165	0.0493	CbGpPWpGaD
Icatibant—ANPEP—female gonad—ovarian cancer	0.0165	0.0283	CbGeAlD
Icatibant—ANPEP—vagina—ovarian cancer	0.0164	0.0281	CbGeAlD
Icatibant—BDKRB2—Validated transcriptional targets of deltaNp63 isoforms—FASN—ovarian cancer	0.0154	0.046	CbGpPWpGaD
Icatibant—ANPEP—testis—ovarian cancer	0.0146	0.0251	CbGeAlD
Icatibant—BDKRB2—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—ovarian cancer	0.0119	0.0356	CbGpPWpGaD
Icatibant—ANPEP—lymph node—ovarian cancer	0.0106	0.0182	CbGeAlD
Icatibant—BDKRB2—Direct p53 effectors—TP63—ovarian cancer	0.0096	0.0286	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—MSH2—ovarian cancer	0.00807	0.0241	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—ATF3—ovarian cancer	0.00801	0.0239	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—SMARCA4—ovarian cancer	0.00754	0.0225	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—MLH1—ovarian cancer	0.00727	0.0217	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—GADD45A—ovarian cancer	0.00644	0.0192	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—MUC16—ovarian cancer	0.00643	0.0192	CbGpPWpGaD
Icatibant—Injection site reaction—Melphalan—ovarian cancer	0.00492	0.0606	CcSEcCtD
Icatibant—Injection site reaction—Vinorelbine—ovarian cancer	0.00429	0.0529	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—INHA—ovarian cancer	0.00414	0.0124	CbGpPWpGaD
Icatibant—ANPEP—C-MYB transcription factor network—CDKN1B—ovarian cancer	0.00412	0.0123	CbGpPWpGaD
Icatibant—ANPEP—C-MYB transcription factor network—CCND1—ovarian cancer	0.00393	0.0117	CbGpPWpGaD
Icatibant—ANPEP—Peptide hormone metabolism—CTNNB1—ovarian cancer	0.00385	0.0115	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—CAV1—ovarian cancer	0.00382	0.0114	CbGpPWpGaD
Icatibant—Dizziness—Altretamine—ovarian cancer	0.00377	0.0464	CcSEcCtD
Icatibant—BDKRB2—Direct p53 effectors—MET—ovarian cancer	0.0037	0.011	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—APC—ovarian cancer	0.00348	0.0104	CbGpPWpGaD
Icatibant—ANPEP—C-MYB transcription factor network—NRAS—ovarian cancer	0.00338	0.0101	CbGpPWpGaD
Icatibant—Nausea—Altretamine—ovarian cancer	0.00338	0.0417	CcSEcCtD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—PIK3CG—ovarian cancer	0.00331	0.00988	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—APC—ovarian cancer	0.00331	0.00988	CbGpPWpGaD
Icatibant—ANPEP—C-MYB transcription factor network—MYC—ovarian cancer	0.00315	0.0094	CbGpPWpGaD
Icatibant—Body temperature increased—Carboplatin—ovarian cancer	0.00311	0.0383	CcSEcCtD
Icatibant—BDKRB2—Direct p53 effectors—MMP2—ovarian cancer	0.00308	0.0092	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—TUBB3—ovarian cancer	0.00292	0.00871	CbGpPWpGaD
Icatibant—ANPEP—C-MYB transcription factor network—KRAS—ovarian cancer	0.00291	0.00869	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—PIK3CD—ovarian cancer	0.00291	0.00868	CbGpPWpGaD
Icatibant—Injection site reaction—Paclitaxel—ovarian cancer	0.00289	0.0356	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—HSD17B6—ovarian cancer	0.00277	0.00827	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—ovarian cancer	0.00257	0.00767	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—PIK3CB—ovarian cancer	0.00254	0.00757	CbGpPWpGaD
Icatibant—ANPEP—C-MYB transcription factor network—HRAS—ovarian cancer	0.00247	0.00738	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—ATF3—ovarian cancer	0.00246	0.00735	CbGpPWpGaD
Icatibant—Injection site reaction—Docetaxel—ovarian cancer	0.00245	0.0302	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—DLC1—ovarian cancer	0.00236	0.00703	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—PTEN—ovarian cancer	0.0023	0.00687	CbGpPWpGaD
Icatibant—BDKRB2—Peptide ligand-binding receptors—CXCL8—ovarian cancer	0.00201	0.00599	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—NRAS—ovarian cancer	0.00196	0.00584	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—BCL9—ovarian cancer	0.00192	0.00573	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—MAPK3—ovarian cancer	0.00187	0.00559	CbGpPWpGaD
Icatibant—BDKRB2—Direct p53 effectors—EGFR—ovarian cancer	0.00187	0.00559	CbGpPWpGaD
Icatibant—Anaphylactic shock—Topotecan—ovarian cancer	0.0018	0.0222	CcSEcCtD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—MAPK1—ovarian cancer	0.00178	0.00532	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—EGFR—ovarian cancer	0.00178	0.00532	CbGpPWpGaD
Icatibant—Nervous system disorder—Topotecan—ovarian cancer	0.00177	0.0218	CcSEcCtD
Icatibant—Anaphylactic shock—Melphalan—ovarian cancer	0.00176	0.0217	CcSEcCtD
Icatibant—BDKRB2—G alpha (i) signalling events—CXCL8—ovarian cancer	0.00169	0.00505	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—KRAS—ovarian cancer	0.00168	0.00502	CbGpPWpGaD
Icatibant—Injection site reaction—Epirubicin—ovarian cancer	0.00165	0.0203	CcSEcCtD
Icatibant—Body temperature increased—Chlorambucil—ovarian cancer	0.0016	0.0197	CcSEcCtD
Icatibant—BDKRB2—Direct p53 effectors—TP53—ovarian cancer	0.00157	0.00469	CbGpPWpGaD
Icatibant—BDKRB2—Regulation of Actin Cytoskeleton—PIK3CA—ovarian cancer	0.00155	0.00461	CbGpPWpGaD
Icatibant—Anaphylactic shock—Vinorelbine—ovarian cancer	0.00154	0.019	CcSEcCtD
Icatibant—Injection site reaction—Doxorubicin—ovarian cancer	0.00153	0.0188	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—DOK1—ovarian cancer	0.00152	0.00453	CbGpPWpGaD
Icatibant—Nervous system disorder—Vinorelbine—ovarian cancer	0.00151	0.0186	CcSEcCtD
Icatibant—Hypersensitivity—Chlorambucil—ovarian cancer	0.00149	0.0184	CcSEcCtD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—ovarian cancer	0.00146	0.00435	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PPP1CC—ovarian cancer	0.00143	0.00426	CbGpPWpGaD
Icatibant—Body temperature increased—Topotecan—ovarian cancer	0.00142	0.0175	CcSEcCtD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—ovarian cancer	0.0014	0.00417	CbGpPWpGaD
Icatibant—BDKRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	0.00135	0.00402	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	0.00133	0.00397	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	0.00133	0.00396	CbGpPWpGaD
Icatibant—Hypersensitivity—Topotecan—ovarian cancer	0.00133	0.0164	CcSEcCtD
Icatibant—Hypersensitivity—Melphalan—ovarian cancer	0.0013	0.016	CcSEcCtD
Icatibant—BDKRB2—G alpha (q) signalling events—PIK3CA—ovarian cancer	0.00129	0.00385	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	0.00126	0.00375	CbGpPWpGaD
Icatibant—Body temperature increased—Vinorelbine—ovarian cancer	0.00122	0.015	CcSEcCtD
Icatibant—Nausea—Chlorambucil—ovarian cancer	0.0012	0.0148	CcSEcCtD
Icatibant—Dizziness—Topotecan—ovarian cancer	0.00119	0.0147	CcSEcCtD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	0.00115	0.00344	CbGpPWpGaD
Icatibant—Rash—Topotecan—ovarian cancer	0.00114	0.014	CcSEcCtD
Icatibant—Hypersensitivity—Vinorelbine—ovarian cancer	0.00114	0.014	CcSEcCtD
Icatibant—Dermatitis—Topotecan—ovarian cancer	0.00113	0.014	CcSEcCtD
Icatibant—Headache—Topotecan—ovarian cancer	0.00113	0.0139	CcSEcCtD
Icatibant—Rash—Melphalan—ovarian cancer	0.00111	0.0137	CcSEcCtD
Icatibant—Dermatitis—Melphalan—ovarian cancer	0.00111	0.0137	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—HDAC6—ovarian cancer	0.00108	0.00323	CbGpPWpGaD
Icatibant—Nausea—Topotecan—ovarian cancer	0.00107	0.0132	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—PPP2R1A—ovarian cancer	0.00107	0.00318	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	0.00107	0.00318	CbGpPWpGaD
Icatibant—Nausea—Melphalan—ovarian cancer	0.00105	0.0129	CcSEcCtD
Icatibant—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00104	0.0128	CcSEcCtD
Icatibant—BDKRB2—GPCR ligand binding—CXCL8—ovarian cancer	0.00103	0.00306	CbGpPWpGaD
Icatibant—BDKRB2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	0.00102	0.00305	CbGpPWpGaD
Icatibant—Dizziness—Vinorelbine—ovarian cancer	0.00102	0.0126	CcSEcCtD
Icatibant—Nervous system disorder—Paclitaxel—ovarian cancer	0.00102	0.0125	CcSEcCtD
Icatibant—Rash—Vinorelbine—ovarian cancer	0.000972	0.012	CcSEcCtD
Icatibant—Dermatitis—Vinorelbine—ovarian cancer	0.000971	0.012	CcSEcCtD
Icatibant—Headache—Vinorelbine—ovarian cancer	0.000965	0.0119	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—YAP1—ovarian cancer	0.000958	0.00286	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—MMP2—ovarian cancer	0.000949	0.00283	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—XIAP—ovarian cancer	0.000938	0.0028	CbGpPWpGaD
Icatibant—Nausea—Vinorelbine—ovarian cancer	0.000915	0.0113	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—SMARCA4—ovarian cancer	0.000914	0.00273	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—EREG—ovarian cancer	0.000892	0.00266	CbGpPWpGaD
Icatibant—Anaphylactic shock—Docetaxel—ovarian cancer	0.000879	0.0108	CcSEcCtD
Icatibant—Nervous system disorder—Docetaxel—ovarian cancer	0.000862	0.0106	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—PGR—ovarian cancer	0.000836	0.00249	CbGpPWpGaD
Icatibant—Body temperature increased—Paclitaxel—ovarian cancer	0.000819	0.0101	CcSEcCtD
Icatibant—ANPEP—Metabolism of proteins—CXCL8—ovarian cancer	0.000789	0.00235	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PIK3CG—ovarian cancer	0.000787	0.00235	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PARP1—ovarian cancer	0.000777	0.00232	CbGpPWpGaD
Icatibant—Hypersensitivity—Paclitaxel—ovarian cancer	0.000764	0.00941	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—IL6ST—ovarian cancer	0.000744	0.00222	CbGpPWpGaD
Icatibant—ANPEP—Metabolism of proteins—CTNNB1—ovarian cancer	0.000727	0.00217	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PIK3CG—ovarian cancer	0.000715	0.00213	CbGpPWpGaD
Icatibant—Body temperature increased—Docetaxel—ovarian cancer	0.000695	0.00856	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—PIK3CD—ovarian cancer	0.000692	0.00206	CbGpPWpGaD
Icatibant—Dizziness—Paclitaxel—ovarian cancer	0.000685	0.00845	CcSEcCtD
Icatibant—Rash—Paclitaxel—ovarian cancer	0.000654	0.00805	CcSEcCtD
Icatibant—Dermatitis—Paclitaxel—ovarian cancer	0.000653	0.00805	CcSEcCtD
Icatibant—Headache—Paclitaxel—ovarian cancer	0.000649	0.008	CcSEcCtD
Icatibant—Hypersensitivity—Docetaxel—ovarian cancer	0.000647	0.00798	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—PPP2R1A—ovarian cancer	0.000631	0.00188	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—PIK3CD—ovarian cancer	0.000628	0.00187	CbGpPWpGaD
Icatibant—Nausea—Paclitaxel—ovarian cancer	0.000616	0.00759	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—PIK3CB—ovarian cancer	0.000603	0.0018	CbGpPWpGaD
Icatibant—Anaphylactic shock—Epirubicin—ovarian cancer	0.000593	0.0073	CcSEcCtD
Icatibant—Nervous system disorder—Epirubicin—ovarian cancer	0.000581	0.00716	CcSEcCtD
Icatibant—Dizziness—Docetaxel—ovarian cancer	0.000581	0.00716	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—CXCL8—ovarian cancer	0.000579	0.00173	CbGpPWpGaD
Icatibant—Rash—Docetaxel—ovarian cancer	0.000554	0.00683	CcSEcCtD
Icatibant—BDKRB2—GPCR downstream signaling—IL2—ovarian cancer	0.000554	0.00165	CbGpPWpGaD
Icatibant—Dermatitis—Docetaxel—ovarian cancer	0.000553	0.00682	CcSEcCtD
Icatibant—Headache—Docetaxel—ovarian cancer	0.00055	0.00678	CcSEcCtD
Icatibant—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000548	0.00676	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—PIK3CB—ovarian cancer	0.000547	0.00163	CbGpPWpGaD
Icatibant—Nervous system disorder—Doxorubicin—ovarian cancer	0.000538	0.00663	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—CXCL8—ovarian cancer	0.000526	0.00157	CbGpPWpGaD
Icatibant—Nausea—Docetaxel—ovarian cancer	0.000522	0.00643	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—IL2—ovarian cancer	0.000503	0.0015	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—TERT—ovarian cancer	0.000501	0.00149	CbGpPWpGaD
Icatibant—Body temperature increased—Epirubicin—ovarian cancer	0.000468	0.00577	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—CAV1—ovarian cancer	0.000463	0.00138	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—ESR1—ovarian cancer	0.000447	0.00133	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—IL6ST—ovarian cancer	0.000439	0.00131	CbGpPWpGaD
Icatibant—Hypersensitivity—Epirubicin—ovarian cancer	0.000437	0.00538	CcSEcCtD
Icatibant—Body temperature increased—Doxorubicin—ovarian cancer	0.000433	0.00534	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—PIK3CG—ovarian cancer	0.000422	0.00126	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—APC—ovarian cancer	0.000422	0.00126	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—NRAS—ovarian cancer	0.000422	0.00126	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—MAPK3—ovarian cancer	0.000404	0.00121	CbGpPWpGaD
Icatibant—Hypersensitivity—Doxorubicin—ovarian cancer	0.000404	0.00498	CcSEcCtD
Icatibant—Dizziness—Epirubicin—ovarian cancer	0.000392	0.00483	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—MAPK1—ovarian cancer	0.000385	0.00115	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—EGFR—ovarian cancer	0.000385	0.00115	CbGpPWpGaD
Icatibant—Rash—Epirubicin—ovarian cancer	0.000374	0.0046	CcSEcCtD
Icatibant—Dermatitis—Epirubicin—ovarian cancer	0.000373	0.0046	CcSEcCtD
Icatibant—Headache—Epirubicin—ovarian cancer	0.000371	0.00457	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—PIK3CD—ovarian cancer	0.000371	0.00111	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—PIK3CA—ovarian cancer	0.000368	0.0011	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—KRAS—ovarian cancer	0.000363	0.00108	CbGpPWpGaD
Icatibant—Dizziness—Doxorubicin—ovarian cancer	0.000363	0.00447	CcSEcCtD
Icatibant—Nausea—Epirubicin—ovarian cancer	0.000352	0.00434	CcSEcCtD
Icatibant—Rash—Doxorubicin—ovarian cancer	0.000346	0.00426	CcSEcCtD
Icatibant—Dermatitis—Doxorubicin—ovarian cancer	0.000345	0.00426	CcSEcCtD
Icatibant—Headache—Doxorubicin—ovarian cancer	0.000344	0.00423	CcSEcCtD
Icatibant—BDKRB2—Signaling by GPCR—PIK3CA—ovarian cancer	0.000334	0.000996	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—ERBB2—ovarian cancer	0.000328	0.000978	CbGpPWpGaD
Icatibant—Nausea—Doxorubicin—ovarian cancer	0.000326	0.00401	CcSEcCtD
Icatibant—BDKRB2—Signaling Pathways—MTOR—ovarian cancer	0.000323	0.000965	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PIK3CB—ovarian cancer	0.000323	0.000965	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CXCL8—ovarian cancer	0.000311	0.000927	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—HRAS—ovarian cancer	0.000309	0.000921	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CDKN1B—ovarian cancer	0.000304	0.000906	CbGpPWpGaD
Icatibant—BDKRB2—GPCR downstream signaling—AKT1—ovarian cancer	0.0003	0.000896	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CASP3—ovarian cancer	0.000297	0.000887	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—IL2—ovarian cancer	0.000297	0.000886	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—IL6—ovarian cancer	0.000296	0.000882	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CCND1—ovarian cancer	0.00029	0.000864	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—CTNNB1—ovarian cancer	0.000287	0.000855	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MMP9—ovarian cancer	0.000281	0.000839	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PTEN—ovarian cancer	0.000279	0.000834	CbGpPWpGaD
Icatibant—BDKRB2—Signaling by GPCR—AKT1—ovarian cancer	0.000273	0.000813	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—VEGFA—ovarian cancer	0.000252	0.000753	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—STAT3—ovarian cancer	0.00025	0.000746	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—NRAS—ovarian cancer	0.000249	0.000744	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MAPK3—ovarian cancer	0.000239	0.000712	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MYC—ovarian cancer	0.000232	0.000693	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—MAPK1—ovarian cancer	0.000227	0.000678	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—EGFR—ovarian cancer	0.000227	0.000678	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—KRAS—ovarian cancer	0.000215	0.00064	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—PIK3CA—ovarian cancer	0.000197	0.000588	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—TP53—ovarian cancer	0.000191	0.000569	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—HRAS—ovarian cancer	0.000182	0.000544	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—IL6—ovarian cancer	0.000175	0.000521	CbGpPWpGaD
Icatibant—BDKRB2—Signaling Pathways—AKT1—ovarian cancer	0.000161	0.000481	CbGpPWpGaD
